Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Back to dashboard
Company Information
About this company
Key people
Mats Blom
Independent Chairman of the Board
Tiago Nunes
Chief Medical Officer
Margarida Duarte
Independent Director
Gunilla Osswald
Independent Director
Behshad Sheldon
Independent Director
Birgitte Volck
Independent Director
Nicklas Westerholm
Chief Executive Officer
Yilmaz Mahshid
Chief Financial Officer
Anny Bedard
President of Egetis North America
Katayoun Welin-Berger
Vice President - Technical Operations
Karl Hard
Vice President, Head - Investor Relations and Communications
Henrik Krook
Vice President - Commercial Operations
Christian Sonesson
Vice President - Product Strategy and Development
Nils Hallen
Human Resources Manager
Click to see more
Key facts
- Shares in issue395.16m
- EPICEGTX
- ISINSE0003815604
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capSEK 4.28bn
- Employees56
- ExchangeStockholm Stock Exchange
- IndexSX All Share PI Market Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.